Ainos reclassified under tech sector following AI smell digitization

SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD) has been reclassified under the Global Industry Classification Standard (GICS) to Technology Hardware, Storage & Peripherals (Code 45202030), effective October 1, 2025, the company announced Thursday.

The update, administered by S&P Dow Jones Indices and MSCI, marks Ainos’ transition from biotechnology to digital olfaction, reflecting its focus on AI-powered scent digitization technology.

The company’s AI Nose platform uses a smell language model to convert scent into machine-readable data for applications across semiconductors, robotics, manufacturing, and healthcare sectors.

Ainos reported a 435% year-over-year revenue increase in the first half of 2025, driven by senior care initiatives in Japan. The company also secured its first multi-year SmellTech-as-a-Service subscription contract valued at $2.1 million for semiconductor manufacturing applications. According to InvestingPro data, the company maintains a healthy current ratio of 2.88, though it faces challenges with cash burn and profitability. InvestingPro subscribers have access to 8 additional key insights about Ainos’s financial health.

The firm has established partnerships with five industrial companies: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology and ugo, Inc. to expand adoption of its technology.

"Our reclassification under GICS is a recognition of Ainos’ transformation into a technology company and our growing leadership in AI-powered scent digitization," said Eddy Tsai, Chairman, President, and Chief Executive Officer of Ainos, according to the press release. The stock has shown strong momentum with a 29% gain over the past six months, though InvestingPro analysis suggests the stock is currently trading above its Fair Value. Discover more detailed valuation metrics and growth potential with an InvestingPro subscription.

The company’s AI Nose platform combines MEMS sensor arrays with AI algorithms to detect scent at parts-per-billion sensitivity and convert analog scent data into actionable insights.

Ainos, Inc. continues to develop VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, maintaining aspects of its biotechnology origins alongside its new technology focus.

In other recent news, Ainos, Inc. has made significant strides with its AI-powered scent technology, securing seven new patents in Europe, Germany, Taiwan, and China. This achievement brings the company’s total active patents to 123, covering various aspects of its scent digitization technology. Additionally, Ainos has filed a prospectus supplement with the SEC to offer and sell up to $874,496 of additional common stock through an at-the-market offering agreement with H.C. Wainwright & Co., LLC. The company had previously increased the aggregate offering price to $1,840,350, with almost the entire amount already sold.

Ainos also announced a three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd., marking its first commercial success in semiconductor manufacturing. This agreement involves deploying 1,400 AI Nose units across ASE’s manufacturing sites in Taiwan. In another development, Ainos plans to deploy robots equipped with its AI Nose technology across seven industrial sites in Japan in partnership with ugo, Inc. These robots will be used in various sectors, including pharmaceutical manufacturing and energy operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.